Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

August 31, 2017August 31, 2017

Blood Levels of Cytokine May Predict Severity of Lung Disease in Early-stage Systemic Sclerosis Patients

High levels of a cytokine called CCL2 circulating in the blood can predict how quickly and severely lung disease will progress in people in the early stages of systemic sclerosis ... Read more

August 24, 2017August 24, 2017

Adempas May Help PAH-SSc Patients When Adcirca Fails, Case Report Suggests

News

Switching to Adempas (riociguat) is a potential therapeutic option for patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who failed to improve when treated with phosphodiesterase ... Read more

April 11, 2017April 11, 2017

100th Patient Enrolled in Inventiva’s Phase 2b Systemic Sclerosis Trial

News

A key milestone has been achieved in the development of Inventiva’s IVA337, an anti-fibrotic drug for treating systemic sclerosis (SSc), with the enrollment of the 100th patient in the Phase 2b ... Read more

March 30, 2017March 30, 2017

Epstein-Barr Virus Infection May Activate Immune Cells in Scleroderma, Study Shows

News

Activation of certain immune cells in scleroderma (SSc) may be linked to infection with Epstein-Barr virus (EBV), researchers showed. The study, “Epstein-Barr virus lytic infection promotes activation of Toll-like ... Read more

January 17, 2017January 17, 2017

Immunosuppressive Therapy Helps Systemic Sclerosis Patients With Lung Disease

News

Levels of the cytokine CXCl4 in the bloodstream drop sharply in response to immunosuppressive therapy, and are associated with improved lung function in systemic sclerosis (SSc) patients with interstitial ... Read more

December 13, 2016December 13, 2016

Way of Easing Fibrosis in Systemic Sclerosis Seen in Treatment Targeting Cell Nucleus in Mice Study

News

Activating a class of nuclear receptors, called peroxisome proliferator-activated receptors (PPARs), with the drug IVA337 eased fibrosis in an animal model of systemic sclerosis, researchers reported. The study, “Pan PPAR ... Read more

November 29, 2016November 29, 2016

Lung Fibrosis Linked to Specific Cytokines in Systemic Sclerosis Patients

News

Researchers found that increased levels of Th-17 cytokines are associated with interstitial lung disease in patients with systemic sclerosis (SSc). Targeting this group of cytokines may improve lung inflammation ... Read more

November 17, 2016November 17, 2016

Samumed’s Scleroderma Therapy Candidate Shows Potential as Topical Treatment

News

Samumed has recently presented promising results on investigative product SM04755, a small molecule that modulates cells’ Wnt pathway, showing the drug’s potential use as a treatment for scleroderma. Samumed, a pharmaceutical company ... Read more

November 8, 2016November 8, 2016

Topical Scleroderma Medicine Seen to Lessen Fibrosis and Inflammation in Mouse Model

News

A new topical medicine, called SM04755, significantly decreased and even reversed fibrosis and inflammation in in vitro and in vivo mouse studies of scleroderma. These results suggest SM04755 is a potential ... Read more

June 21, 2016June 21, 2016

Phase 2 Study of Resunab to Treat Systemic Sclerosis Now Fully Enrolled, Corbus Reports

News

Corbus Pharmaceuticals recently announced that its Phase 2 clinical trial assessing the drug Resunab as a potential treatment for diffuse cutaneous systemic sclerosis is now fully enrolled. The study (NCT02465437) is a randomized, ... Read more